Contents

Main Program

Joint Symposium

The Joint-Symposium with the 44th Annual Meeting of Japanese Society of Gout and Nucleic Acid Metabolism is held.

Joint-Symposium: Current therapy for gout and hyperuricemia in the world

1. Hitoshi Endou (Kyorin University / J-Pharma Co. Ltd., Japan)
   Uricosuric agents and renal tubular transporters
2. Naoyuki Kamatani (Center for Genomic Medicine, RIKEN Yokohama Institute, Japan)
   Febuxostat; a non-purine xanthine oxidase inhibitor useful for the treatment of gout and hyperuricemia
3. Masayuki Hakoda (Yasuda Women's University, Japan)
   Implication of xanthine oxidase-inhibiting therapy for non-gouty conditions
4. Weigang Fang (Peking Union Medical College Hospital, China)
   The current practice of gout treatment in China
5. Hsiao-Yi Lin (Veterans General Hospital, Taiwan)
   The Updated Strategies in the Management of Hyperuricemia and Gout in Taiwan
6. Michael A. Becker (The University of Chicago, USA)
   Treatment of the hyperuricemia of gout in the United States

Plenary Sessions

Session 1: Role of uric acid in the pathogenesis of cardiovascular and renal diseases

1. Takuya Tsuchihashi (National Kyushu Medical Center, Japan)
   Management of uric acid as a cardiovascular risk in hypertensive patients
2. Masahiko Kato (Tottori University, Japan)
   The role of uric acid as a biomarker for cardiovascular disease
3. Iwao Ohno (Jikei University School of Medicine, Japan)
   Relationship between hyperuricemia and chronic kidney disease
4. Shih-Yang Chen (Center of Gout, Country Hospital, Taiwan)
   The association of uric acid with cardiovascular disease and renal insufficiency in Taiwan

Session 2: Clinical topics of gout and hyperuricemia

1. Shih-Yang Chen (Center of Gout, Country Hospital, Taiwan)
   Gout and Hyperuricemia in Taiwan
2. Ikuo Mineo (Toyonaka Municipal Hospital, Japan)
   Significance of Metabolic Syndrome in People with Hyperuricemia or Gout
3. Bruce N. Cronstein (NYU School of Medicine, USA)
   The role of purines in the pathogenesis of alcoholic liver disease
4. Masaru Kubota (Nara Women's University, Japan)
   Investigation on hyperuricemia in children with obesity and various pediatric diseases
5. Hisashi Yamanaka (Tokyo Women's Medical University, Japan)
   'Guideline for the management of hyperuricemia and gout' by Japanese Society of Gout and Nucleic Acid Metabolism.

Session 3: Association between genomic variation and urate metabolism

1. Naoyuki Kamatani (RIKEN Center for Genomic Medicine, Japan)
   Genome-wide association studies to identify genes associated with various traits as well as to identify new drug targets or the new targets of pre-existing drugs
2. Hirotaka Matsuo (National Defense Medical College, Japan)
   ABCG2/BCRP dysfunction as a major cause for gout
3. Naohiko Anzai (Kyorin University School of Medicine, Japan)
   Renal urate reabsorptive transporters: putative roles for the onset of hyperuricemia
4. Atsuo Taniguchi (Tokyo Women's Medical University, Japan)
   Genetic polymorphisms and gout in Japanese patients
5. Christian Gieger (Helmholtz Zentrum München (GmbH), Germany)
   Genome-wide perspective of genetic variation in human metabolism with potential implications for biomedical and pharmaceutical research

Session 4. Recent Advances in Purine/Pyrimidine Enzyme Regulation, Enzyme and Regulation of Metabolism

1. Takayuki Morisaki (Research Institute, National Cerebral and Cardiovascular Center, Japan)
   Murine AMPD3 deficiency: Elevation of erythrocyte ATP does not improve anemia due to PK deficiency
2. Peili Li (Tottori University, Japan)
   AMP deaminase 3 plays a critical role in remote reperfusion lung injury
3. Ryszard T Smolenski (Medical University of Gdansk, Poland)
   Knock-out of AMP deaminase is cardioprotective in experimental acute ischemia
4. John A. Duley (The University of Queensland / Mater Medical Research Institute, Australia)
   The PRPP synthetase neuropathology spectrum: What can we learn from it?
5. Löffler Monika (Philipps-University Marburg, Germany)
   Cell-specific expression of dihydropyrimidine dehydrogenase in brain and peripheral tissues
6. Moritz Schmelzle (Beth Israel Deaconess Medical Center)

Session 5: Purines/Pyrimidines and Cancer

1. William B. Parker (Southern Research Institute, USA)
   Fludarabine phosphate in Conjunction with E. coli Purine Nucleoside Phosphorylase for the treatment of solid tumors.
2. Yehuda G. Assaraf (Technion-Israel Institute of Technology, Israel)
   hnRNP H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance
3. Takahiro Yamauchi (University of Fukui, Japan)
   Pharmacologically directed optimization of the use of nucleoside analogs for leukemia therapy.
4. G.J. Peters (VU University Medical Center, The Netherlands)
   Drug delivery as a successful approach to improve the efficacy of antimetabolites
5. Richard I Christopherson (University of Sydney, Australia)
   Cladribine and fludarabine induce endoplasmic reticulum stress in human Raji lymphoma cells
6. Elisa Giovannetti (VU University Medical Center, Amsterdam, The Netheland)
   MiR-21: biomarker of outcome and determinant of resistance to gemcitabine and 5-fluorouracil in pancreas cancer

Session 6: Protein Structure and Catalytic Mechanism

1. Britt-Marie Sjöberg (Stockholm University, Sweden)
   Ribonucleotide reductases as targets for novel antimicrobials
2. Sondra H. Berger (University of South Carolina, USA)
   Conformational Switching of Human Thymidylate Synthase Leads to Novel Targeting Approaches
3. Ken Okamoto (Nippon Medical School, Japan)
   Reaction mechanism and substrate binding mode of xanthine oxidoreductase.
4. Liya Wang (Swedish University of Agricultural Sciences, Sweden)
   Enzyme-bound feedback inhibitor affects the substrate selectivity of human mitochondrial thymidine kinase 2

Session 7: Inborn Errors of metabolism / Molecular Mechanisms of Disease

1. Vanna Micheli (University of Siena, Italy)
   Anne Simmonds' Memorial Lecture (introduction given by David Perrett)
   INBORN ERRORS OF PURINE AND PYRIMIDINE METABOLISM: HOW MUCH WE OWE TO H. ANNE SIMMONDS
2. Yasukazu Yamada (Aichi Human Service Center, Japan)
   Hypoxanthine guanine phosphoribosyltranferase (HPRT) deficiencies in Asian population
3. Maria Grazia Tozzi (the University of Pisa, Italy)
   Inborn errors in purine metabolism: role of 5'-nucleotidases and their involvement in the aetiology of neurological impairments.
4. Atsuo Taniguchi (Tokyo Women's Medical University, Japan)
   Novel mutations in the UMOD gene causing familial juvenile hyperuricemic nephropathy in two Japanese families.
5. Makoto Yasuda (Teikyo University, Japan)
   Detection of mutant uromodulin in transgenic mouse harboring mutant human UMOD gene
6. Andre Van Kuilenburg (Academic Medical Center, The Netherlands)
   DIHYDROPYRIMIDINASE DEFICIENCY: PHENOTYPE, GENOTYPE AND STRUCTURAL CONSEQUENCES IN 17 PATIENTS
7. Anthony Marinaki (St Thomas Hospital, UK)
   Next generation molecular diagnostic techniques

Session 8: Transport of Purine and Pyrimidine

1. Promsuk Jutabha (Kyorin University School of Medicine, Japan)
   Apical voltage-driven urate efflux transporter NPT4 in renal proximal tubule
2. Michael F. Wempe (School of Pharmacy University of Colorado Denver, USA)
   Uric Acid Transport: Developing potent inhibitors
3. Atsushi Hosomi (Kanazawa University, Japan)
   Extra-renal excretion of uric acid in rats
4. Katsuhisa Inoue (Nagoya City University, Japan)
   Molecular mechanism of intestinal nucleobase transport in mammals.
5. Paula Fernández-Calotti (University of Barcelona, Spain)
   Improvement of purine-based anticancer therapy by enhancing the uptake of the adenosine analogue fludarabine

PAGE TOP